Drug intelligence / Profile preview

Downtuss AD

Development stage
Unknown
Lead developer
Healthkind Labs
Modality
Small Molecules
Administration
Oral
01

Overview

Downtuss AD is a combination oral liquid formulation developed by Healthkind Labs for the symptomatic relief of cough, cold, and upper respiratory tract congestion. It contains five active ingredients: dextromethorphan (a cough suppressant), ambroxol (a mucolytic agent), chlorpheniramine (an antihistamine), phenylephrine (a nasal decongestant), and menthol (a cooling agent). Dextromethorphan acts as a sigma-1 receptor agonist and NMDA receptor antagonist to suppress the cough reflex. Ambroxol reduces mucus viscosity and enhances mucociliary clearance, while also blocking voltage-gated sodium channels (Nav1.7 and Nav1.8) to provide local anesthetic effects. Chlorpheniramine competitively inhibits histamine H1 receptors to alleviate allergic symptoms such as sneezing and rhinorrhea. Phenylephrine is a selective alpha-1 adrenergic receptor agonist that induces vasoconstriction in the nasal mucosa, reducing swelling and congestion. Menthol acts as a TRPM8 agonist, providing a cooling sensation that helps soothe throat irritation.

Brand names
Downtuss AD
Other names
Downtuss-ADdextromethorphan + ambroxol + chlorpheniramine + phenylephrine + menthol
02

Targets

ADRA1A (α1A)GBA1 (Glucosylceramidase)HRH1 (Histamine H1 Receptor)SIGMAR1 (Sigma non-opioid intracellular receptor 1)SCN10A (Sodium channel protein type X alpha subunit)SCN9A (Sodium channel protein type 9 subunit alpha)TRPM8 (Transient receptor potential cation channel subfamily M member 8)ADRA1B (α1B)ADRA1D (α1D)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on Downtuss AD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Downtuss AD.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call